Navigation Links
Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008

Company to Conduct Conference Call and Webcast

LEXINGTON, Mass., July 29 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) will announce its third quarter 2008 financial results in a press release to be issued before market open on August 5, 2008. The Company will host a conference call and webcast to discuss these results at 9:00 AM eastern time on August 5, 2008.

The live call may be accessed by dialing 888-713-4215 from the U.S. and Canada, and 617-213-4867 from international locations. The participant passcode is 53319745. A replay of the call will be available beginning at 11:00 AM on August 5, 2008 and lasting until 12:00 AM on September 5, 2008. To access the replay, please dial 888-286-8010 from the U.S. and Canada, and 617-801-6888 from international locations, using the passcode 72001555.

The press release and the live webcast will be accessible by visiting the Investors section of the Company's website, An archived version of the call will be accessible at the same web address for 30 days following the live call.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and the octreotide implant for acromegaly.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS and SUPPRELIN LA; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; need for additional funds and corporate partners, including for the development of our products; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; difficulties in managing our growth; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. Indevus undertakes no obligation to publicly update any forward- looking statement, whether as a result of new information, future events or otherwise.


Michael W. Rogers Robin L. DeCarlo

Executive Vice President and CFO Director, Corp. Communications

(781) 861-8444 (781) 402-3405

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
2. Indevus Announces Management Changes
3. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
4. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
5. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
6. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
7. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
8. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
9. Indevus Announces Allergan as New Partner for SANCTURA Brand
10. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
11. VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC
Post Your Comments:
(Date:12/1/2015)... 2015 ) ... U.K. Virology and Bacteriology Testing Market: Sales ... Supplier Shares by Test, Innovative Technologies, Competitive ... --> ) has announced ... and Bacteriology Testing Market: Sales and Volume ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells ... stages of a new closed system for isolating adipose-derived stem cells. The announcement starts ... (SVF) of adipose tissue. SVF is a component of the lipoaspirate obtained from liposuction ...
(Date:11/30/2015)... ... 2015 , ... Global Stem Cells Group announced the opening of a new core ... and Iquique in northern Chile. The facilities are part of GSCG’s expansion efforts in Latin ... techniques in stem cell medicine to patients from around the world. , The clinics will ...
(Date:11/30/2015)... (NYSE: BIOA ), a leader in renewable materials, today ... Climate Pledge, alongside more than 140 companies from across the ... demonstrate an ongoing commitment to climate action and to voice ... Paris climate negotiations. Sarnia, Canada ... --> BioAmber uses biotechnology to convert renewable sugars ...
Breaking Biology Technology:
(Date:10/29/2015)... Oct. 29, 2015  Connected health pioneer, Joseph ... explosion of technology-enabled health and wellness, and the business ... The Internet of Healthy Things . ... smartphones even existed, Dr. Kvedar, vice president, Connected Health, ... care delivery, moving care from the hospital or doctor,s ...
(Date:10/27/2015)... , Oct. 27, 2015 In the ... issues of concern for various industry verticals such as ... due to the growing demand for secure & simplified ... various ,sectors, such as hacking of bank accounts, misuse ... electronic equipment such as PC,s, laptops, and smartphones are ...
(Date:10/26/2015)... , October 26, 2015 /PRNewswire/ ... --> adds Biometrics ... to 2021 as well as Emerging ... research reports to its collection of ... . --> ...
Breaking Biology News(10 mins):